Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-8931-3429
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Sol Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions
What is Sol Gel Technologies' stock symbol?
Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."
How were Sol Gel Technologies' earnings last quarter?
Sol Gel Technologies Ltd (NASDAQ:SLGL) announced its earnings results on Tuesday, August, 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.06. The company had revenue of $7.79 million for the quarter, compared to analysts' expectations of $7 million. Sol Gel Technologies had a negative return on equity of 67.88% and a negative net margin of 300.12%. View Sol Gel Technologies' Earnings History.
When is Sol Gel Technologies' next earnings date?
What price target have analysts set for SLGL?
1 equities research analysts have issued 12 month price targets for Sol Gel Technologies' shares. Their forecasts range from $23.00 to $23.00. On average, they expect Sol Gel Technologies' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 165.0% from the stock's current price. View Analyst Price Targets for Sol Gel Technologies.
What is the consensus analysts' recommendation for Sol Gel Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sol Gel Technologies.
What are Wall Street analysts saying about Sol Gel Technologies stock?
Here are some recent quotes from research analysts about Sol Gel Technologies stock:
- 1. According to Zacks Investment Research, "Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. " (7/19/2019)
- 2. HC Wainwright analysts commented, "We have valued Sol-Gel based on a discounted cash flow (DCF) analysis. This yields a value of $139M for TWIN, assuming a 50% probability of success, and a $245M valuation for Epsolay, assuming a 60% probability of success. Sol-Gel’s partnered generic products contribute an aggregate of $42M." (6/24/2019)
Has Sol Gel Technologies been receiving favorable news coverage?
Press coverage about SLGL stock has trended negative this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sol Gel Technologies earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Sol Gel Technologies.
Are investors shorting Sol Gel Technologies?
Sol Gel Technologies saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 64,800 shares, an increase of 6.2% from the July 31st total of 61,000 shares. Based on an average daily trading volume, of 21,800 shares, the short-interest ratio is currently 3.0 days. Approximately 1.2% of the shares of the company are short sold. View Sol Gel Technologies' Current Options Chain.
Who are some of Sol Gel Technologies' key competitors?
Some companies that are related to Sol Gel Technologies include TG Therapeutics (TGTX), Synthorx (THOR), Akebia Therapeutics (AKBA), Aurinia Pharmaceuticals (AUPH), Revance Therapeutics (RVNC), Akero Therapeutics (AKRO), Organogenesis (ORGO), DiaMedica Therapeutics (DMCAF), Lannett (LCI), Flexion Therapeutics (FLXN), Achillion Pharmaceuticals (ACHN), Myovant Sciences (MYOV), Retrophin (RTRX), Intra-Cellular Therapies (ITCI) and Basilea Pharmaceutica (BPMUF).
What other stocks do shareholders of Sol Gel Technologies own?
Who are Sol Gel Technologies' key executives?
Sol Gel Technologies' management team includes the folowing people:
- Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 58)
- Mr. Gilad Mamlok, Chief Financial Officer (Age 51)
- Mr. Itzik Yosef, VP of Operations (Age 43)
- Dr. Ofer Toledano, VP of R&D (Age 54)
- Dr. Ofra Levy-Hacham Ph.D., VP of Clinical & Regulatory Affairs (Age 53)
When did Sol Gel Technologies IPO?
(SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Jefferies and BMO Capital Markets served as the underwriters for the IPO and JMP Securities and Raymond James were co-managers.
Who are Sol Gel Technologies' major shareholders?
Sol Gel Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Delek Group Ltd. (8.17%), Clal Insurance Enterprises Holdings Ltd (0.33%), Invesco Ltd. (0.07%), BlackRock Inc. (0.06%) and Steward Partners Investment Advisory LLC (0.04%).
Which major investors are buying Sol Gel Technologies stock?
SLGL stock was purchased by a variety of institutional investors in the last quarter, including Delek Group Ltd., Steward Partners Investment Advisory LLC, BlackRock Inc., Clal Insurance Enterprises Holdings Ltd and Invesco Ltd..
How do I buy shares of Sol Gel Technologies?
Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sol Gel Technologies' stock price today?
One share of SLGL stock can currently be purchased for approximately $8.68.
How big of a company is Sol Gel Technologies?
Sol Gel Technologies has a market capitalization of $164.25 million and generates $130,000.00 in revenue each year. The company earns $-32,200,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. View Additional Information About Sol Gel Technologies.
What is Sol Gel Technologies' official website?
How can I contact Sol Gel Technologies?
Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403650. The company can be reached via phone at 972-8931-3429 or via email at [email protected]
MarketBeat Community Rating for Sol Gel Technologies (NASDAQ SLGL)
MarketBeat's community ratings are surveys of what our community members think about Sol Gel Technologies and other stocks. Vote "Outperform" if you believe SLGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
